Biomea Fusion Inc (BMEA)

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat...

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for...

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the...

Form 8-K - Current report

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5...

Form DEF 14A - Other definitive proxy statements

Form ARS - Annual Report to Security Holders

Form 4 - Statement of changes in beneficial ownership of securities

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]